Login / Register

Username:


Password: [Lost?]



New User? Click here for your FREE subscription



Pharmacists
Pharmacists Pharmacists

Follow Us


NEWS-Line on Twitter NEWS-Line on Facebook NEWS-Line on Google+ NEWS-Line on LinkedIn NEWS-Line on Pinterest


Pharmacist Conferences &
Educational Opportunities


Dec. 8 - 12

ASHP Midyear Clinical Meeting

American Society of Health-System Pharmacists

More Events

Adding Immunotherapy After Initial Treatment Can Benefit Metastatic Lung Cancer Patients | NEWS-Line for Pharmacists

Adding Immunotherapy After Initial Treatment Can Benefit Metastatic Lung Cancer Patients


Source:

Treating metastatic non-small cell lung cancer (NSCLC) patients with the immunotherapy drug pembrolizumab after they’ve completed locally ablative therapy – meaning all known sites of their cancer were either treated with surgery, radiation, or other definitive treatments – almost tripled the median progression-free survival (PFS) compared to the historical average. Research from the Abramson Cancer Center at the University of Pennsylvania found the average PFS of study participants was 19.1 months, compared to 6.6 months. JAMA Oncology published the findings today.

Lung cancer is, by far, the leading cause of cancer death in America, and NSCLC is the most common type. Chemotherapy is the standard treatment, but recent data have shown that patients with limited metastatic disease may have more options.

“Multiple trials have shown that if we use these definitive treatment techniques on all visible tumor sites, patients can end up with better outcomes than what they would get with chemotherapy alone, so our trial went one step further and added immunotherapy,” said lead author Joshua M. Bauml, MD, an assistant professor of Hematology-Oncology in Penn’s Perelman School of Medicine. The study’s senior author was Corey J. Langer, MD, a professor of Hematology-Oncology at Penn.

For this study, 45 NSCLC patients with four or fewer metastatic sites underwent LAT, then received pembrolizumab. In addition to the significant increase in overall average PFS, the average PFS from the start of pembrolizumab was 18.7 months.

Importantly, the treatment did not lead to any new safety issues or decreases in patient quality of life.

“Our understanding of which metastatic patients may benefit from curative therapies as opposed to palliative therapies is still evolving, but our data show promise that the addition of immunotherapy can bring make a difference,” Bauml said.

Researchers say the approach needs further study and that they are still evaluating the impact of this combination on overall survival. However, they note that this study accrued 45 patients from February 2015 through September 2017, a significant number for a single site and evidence that a larger, multicenter, randomized controlled trial to test this approach is feasible.

This study was supported by a grant from Merck, which manufactures pembrolizumab, though the company had no role in the conceptualization, data collection, or analysis and interpretation. The study was also supported by an Abramson Cancer Center Core Grant (P30CA016520).

Source:Perelman School of Medicine at the University of Pennsylvania

Photo Credit:Penn Medicine


Post not cached because it doesn't exist


Share This!


Pharmacist Jobs



NAVY MEDICINE - Making a Difference

NAVY MEDICINE
National

NAVY MEDICINE - Making a Difference

NAVY MEDICINE
New York

Navy Medicine Making A Difference

NAVY MEDICINE
National

Navy Medicine Making A Difference

NAVY MEDICINE
National

Navy Medicine Making A Difference

NAVY MEDICINE
National

Pharmacist

Olympic Medical Center
Port Angeles, Washington

More Jobs
(Dismiss) Thank you for visiting NEWS-Line! Please sign up, login, or follow us on your favorite social networks
to receive custom tailored eNews, job listings, and educational opportunities for your specific profession.